Eledon Pharmaceuticals

ELDN Rare disease Lead: Phase 2 1 Biotech Distilled article ↓

Most recent annual filing: 2026-03-19

Catalyst timeline

Tegoprubart kidney Ph3 startlate 2026Tegoprubart kidney Ph3 start, late 2026, notable
Eledon financing2Q 2027Eledon financing, 2Q 2027, routine

Bar width shows how precise the guidance is — a pin is a stated date, a wide band a six-month window. Deeper blue means more of the thesis rides on the event; it is not a view on the stock.

Pipeline (2 active programs)

tegoprubart

Protein Target: CD40L

Kidney Transplant Rejection Phase 2 University of Chicago Medicine NCT06972069
Amyotrophic Lateral Sclerosis Phase 2 intravenous

Discontinued (1)

tegoprubart — IgA Nephropathy · deprioritized; all IgAN clinical development activities were discontinued in 2023

Biotech Distilled coverage (1)

2026-08-14 Eledon Pharmaceuticals (ELDN) — Scientific Deep Dive for Tegoprubart and Pipeline Products 🔒 Paid

Articles open on Substack. Some deep dives are subscriber-only.